Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan

References

• Kralovics R, Passamonti F, Buser AS, Teo S-S, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790.
   Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–3476.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
   PubMed Web of Science ®Google Scholar
• Cortelazzo SVP, Finazzi G, D'Emilio A, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3):556–562.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128–5133.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369–e369.
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15(10):1193–1207.
   PubMed Web of Science ®Google Scholar
• Shimoda K, Takahashi N, Kirito K, Iriyama N, et al. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2020;112(3):268–291.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Edahiro Y, Araki M, Inano T, et al. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan. Eur J Haematol. 2019;102(6):516–520.
   PubMed Web of Science ®Google Scholar
• Edahiro Y, Morishita S, Takahashi K, et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99(5):625–634.
   PubMed Web of Science ®Google Scholar
• Shirane S, Araki M, Morishita S, Edahiro Y, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46–e48.
   PubMed Web of Science ®Google Scholar
• Takei H, Morishita S, Araki M, et al. Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One. 2014;9(8):e104958.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–1210.
   PubMed Web of Science ®Google Scholar
• Claire NH, Campbell PJ, Buck G, et al. Hydroxyurea compared with Anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33–45.
   Web of Science ®Google Scholar
• Hashimoto Y, Nakamae H, Tanaka T, et al. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. Eur J Haematol. 2018;101(4):508–513.
   PubMed Web of Science ®Google Scholar
• Mann N, King T, Murphy R. Review of primary and secondary erythromelalgia. Clin Exp Dermatol. 2019;44(5):477–482.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Szuber N, Pardanani A, et al. Extreme thrombocytosis in low-risk essential thrombocythemia: retrospective review of vascular events and treatment strategies. Am J Hematol. 2021;1(6):96.
   Google Scholar
• Alvarez-Larran A, Pereira A, Arellano-Rodrigo E, et al. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol. 2013;161(6):865–871.
   PubMed Web of Science ®Google Scholar
• Fu R, Xuan M, Lv C, et al. External validation and clinical evaluation of the international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients. Eur J Haematol. 2014;92(6):502–509.
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84(4):215–220.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Ferrari A, Masciulli A, et al. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729–1737.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Rocca B, Tosetto A, et al. The aspirin regimens in essential thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J. 2018;8(6):49.
   PubMedGoogle Scholar